Compounded GLP-1 Rules in 2026: What Changed and What It Means

At a glance

• Ask why an approved medicine cannot meet the individual patient’s medical need.
• 503A pharmacies and 503B outsourcing facilities operate under different conditions.
• FDA registration, accreditation and a test certificate do not establish FDA approval or clinical equivalence.

What changed after the shortages

FDA’s shortage and compounding updates describe the end of the temporary enforcement-discretion periods for semaglutide and tirzepatide. The old shortage-era explanation is not a sufficient answer for a new prescription in October 2026.

The law includes separate conditions for traditional patient-specific pharmacy compounding under section 503A and outsourcing facilities under section 503B. Do not read an exception for one setting as blanket permission for the other. Current FDA guidance and the individual circumstances matter.

Sources: FDA: compounding policy and resolved shortagesFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss NovoCare: current savings termsLillyDirect: weight management

Trace the actual medicine

Obtain the name and address of the dispensing pharmacy, the active ingredient and any additives, the concentration, storage instructions and beyond-use date. Verify licensure with the relevant state authority. Ask the prescriber to explain why that formulation is medically necessary for you.

FDA warns about dosing errors, counterfeit labeling, semaglutide salt forms and poor temperature control during shipment. An online certificate or an assurance that a product has the same active ingredient does not resolve all of those issues.

Sources: FDA: compounding policy and resolved shortagesFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss NovoCare: current savings termsLillyDirect: weight management

Compare the approved pathway too

Manufacturer pharmacy programs and insurance-supported prescriptions provide additional routes to approved medicines. Compare the complete cost and continuity of care before concluding that a compounded product is the only affordable option.

We do not rank compounding pharmacies as clinically equivalent to the approved products. A pharmacy’s marketing is evidence of what it advertises, not independent evidence of outcomes or a legal determination about a particular prescription.

Sources: FDA: compounding policy and resolved shortagesFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss NovoCare: current savings termsLillyDirect: weight management

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. FDA: compounding policy and resolved shortagesMedical or regulatory source · Source reviewed · 2026-10-02
2. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Medical or regulatory source · Source reviewed · 2026-10-05
3. NovoCare: current savings termsMedical or regulatory source · Source reviewed · 2026-10-02
4. LillyDirect: weight managementMedical or regulatory source · Public reference; local capture limited · 2026-10-02